Transurethral Prostate Resection (TURP) vs. Prostate Artery Embolization (PAE)

Launched by UPPSALA UNIVERSITY · Sep 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for men with benign prostatic hyperplasia (BPH), a condition that can cause uncomfortable urinary symptoms. The trial compares a procedure called Transurethral Prostate Resection (TURP) with Prostate Artery Embolization (PAE). The goal is to find out which treatment works better in terms of reducing symptoms, any complications that might arise, costs, and overall quality of life for patients.

To participate in this trial, men aged 16 and older with BPH who haven’t found relief from other medical treatments may be eligible. Key requirements include having a certain level of urinary symptoms and specific measurements of prostate size and urine flow. Participants can expect to undergo either TURP or PAE and will be monitored for their health outcomes throughout the study. This research aims to provide valuable information that could help improve treatment options for men facing these urinary issues.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Benign prostatic hyperplasia where medical treatment has not helped or for other reasons has not been deemed applicable
• • IPSS\>=8
• • Prostate volume \[40-80\] ml measured via transrectal ultrasound
• • Peak flow rate (Qmax) \<= 15 ml / s,
• • Verified obstruction by urodynamic studies (cystometry)
• • Surgery not contraindicated
• Exclusion Criteria:
• • Prostate cancer
• • Severe atherosclerosis
• • Kidney failure
• • Urethral stricture
• • Active cystitis or prostatitis
• • Bladder stone.
• • Neurogenic bladder disorder
• • Contrast product allergy